<DOC>
	<DOCNO>NCT00706537</DOCNO>
	<brief_summary>CP-945598 potent selective Cannabinoid-1 ( CB1 ) receptor antagonist currently develop treatment obesity . CP-945598 also consider potential treatment non-alcoholic steatohepatitis ( NASH ) . This study investigate steady-state safety , toleration pharmacokinetics multiple oral dose administration CP-945598 . Results use estimate pharmacokinetic characteristic NASH patient underwrite safety compound prior study NASH patient .</brief_summary>
	<brief_title>Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Body Mass Index ( BMI ) 25 40 kg/m2 Subjects biopsy evidence NASH 2 year prior screen visit . Hemoglobin ≥11 g/dL , platelet count ≥100,000 cells/mm3 , neutrophil count ≥1,500cells/mm3 . Other form NASH liver disease . Decompensated severe liver disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Pharmacokinetic safety NASH patient</keyword>
</DOC>